v3.26.3
Disaggregated Revenues (Tables)
9 Months Ended
Sep. 30, 2026
Disaggregation of Revenue [Abstract]  
Schedule of Disaggregation of Revenue by Nature
The following table provides information regarding total revenues (dollars in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
(unaudited)(unaudited)
Net product sales
Qelbree$90,824 $81,416 $257,906 $223,708 
GOCOVRI42,650 40,849 115,420 108,198 
ONAPGO17,075 6,806 38,996 8,410 
Trokendi XR10,213 10,043 28,103 34,037 
Oxtellar XR7,957 12,016 24,161 33,851 
APOKYN6,490 10,387 20,541 38,183 
Other(a)
3,367 7,025 9,915 22,138 
Total net product sales178,576 168,542 495,042 468,525 
Collaboration revenue (ZURZUVAE)(b)
41,697 20,164 104,690 20,164 
Royalty, licensing, and other revenues6,498 3,397 53,802 18,691 
Total revenues$226,771 $192,103 $653,534 $507,380 
___________________________________________
(a) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
(b) Includes the Company's proportionate share of net sales of ZURZUVAE.